



Cala Trio Therapy

Cala Trio is the first non-invasive targeted therapy that reduces hand tremors for adults living with Essential Tremor (ET). Prescription therapy is a simple, wrist-worn device that is calibrated to treat a patient’s unique tremor symptoms. When activated, Cala Trio therapy gently stimulates the nerves in the wrist to disrupt the tremulous activity in the brain, without the need for invasive brain surgery or medication.

The easy-to-use and effective Cala Trio therapy can be prescribed through an in-person consultation or telemedicine appointment. Therapy is conveniently delivered to the patient’s home, and Cala Health educates patients based on how they learn—phone, video, user portal.

Cala Therapy, now marketed as Cala Trio therapy, achieved statistically significant improvements in symptomatic relief of ET in the treated hand, as measured by validated physician and patient assessment scales and motion sensor data in the PROSPECT Study.

Cala Trio therapy is indicated to aid in the temporary relief of hand tremors in the treated hand following stimulation in adults with essential tremor.

Caution: Federal law restricts this device to sale by or on the order of a physician.

Prior to use, refer to the product labeling for complete product instructions for use, contraindications, warnings, and precautions at CalaTrio.com/Safety. Always contact your health care provider with any questions or concerns.



At A Glance

- A wrist-worn neuromodulation therapy for ET that delivers individualized treatment via onboard physiologic sensors with durable electrodes.
- First and only non-invasive prescription therapy that goes directly to the source of tremor and is specifically designed to treat ET.
- Condition is marked by hand tremors that make it difficult, if not impossible, to perform daily activities, including eating, drinking, and writing. Cala Trio therapy puts patients in control of their tremor, without the need for invasive brain surgery or drugs.
- Calibrated to each patient’s tremor pattern. When activated, Cala Trio therapy gently stimulates the nerves in the wrist to disrupt the tremulous activity in the brain.
- Received de novo FDA clearance in April 2018, and 510k in October 2021 for the temporary relief of hand tremors in adults with ET.



The Commercial Model



The vertically integrated, patient centric, commercial model was designed with the patient at the center. It is both connected and responsive to deliver a high-quality Cala Trio experience from access to user feedback



Cala Trio therapy can be conveniently prescribed through an in-office consultation or telemedicine appointment for patients diagnosed with essential tremor



Therapy is conveniently delivered to the patient's home, and Cala Health's Customer Success team educates the patient via phone, video, user portal



Therapy is cloud-connected enabling individual patient insights and ongoing study of tremor to inform future treatments for movement disorders

cala
trio™



Milestones

2014

Cala Health founded.

Cala Health initiated proof of concept studies for treating hand tremor in ET.

2016

Multicenter randomized controlled trial completed

2018

Cala therapy was FDA cleared for transient relief of hand tremors in adults with ET.

2019

Cala Health commercialized the Cala Trio therapy for ET in the United States.

Technology Innovations 2019 Best Practices

2020

[Tremor and Other Hyperkinetic Movements](#) publishes **PRO**spective study for **Sym**Ptomatic relief of **Ess**ential tremor with **Cala** Therapy (**PROSPECT**)—the largest therapeutic clinical trial for ET. Data collected from 263 patients from 26 sites using the therapy for 3 months.

2021

[International Essential Tremor Foundation Guidelines for Adults with ET](#)

Two unique Healthcare Common Procedure Coding System (HCPCS) codes in effect for stimulator and band supply